RxDoctor Payments Data

Ryan Owsley, MD

Dermatology · Nampa, IDNPI 1659361681

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 388 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 33.5% of the total.

$8,803in general payments, 2019–2025

Across 388 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$843
  • Sun Pharmaceutical Industries Inc.$829
  • Novartis$737
  • Lilly USA, LLC$476
  • UCB, Inc.$456
  • plus $3K from 29 others
$3,917in research payments, 2019–2025

Across 1 payment — averaging $3916.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Galderma Laboratories, L.p.$4K

What the payments were for

  • Food & beverage$8,33295%
  • Education$4715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,803 in reported general payments places this provider in the 85th percentile of 52 dermatology providers in Idaho.

See all dermatology providers in Idaho

Medicare billing

Part B allowed, 2024
$386,319
Medicare patients
570
Services billed
21,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab11$101,265
Dupixent SyringeDupilumab14$79,408
OtezlaApremilast12$59,444
Doxycycline Hyclate66$2,211
Clobetasol Propionate36$1,532
Metronidazole13$1,043
Fluocinolone Acetonide14$854
Hydroxychloroquine Sulfate19$718
Spironolactone84$717
Betamethasone Dipropionate13$672
MethotrexateMethotrexate Sodium31$662
ValacyclovirValacyclovir Hcl36$607
Triamcinolone Acetonide52$587
Hydrocortisone40$299
Ketoconazole21$230

Paid to pharmacies, not to this prescriber.

Other dermatology in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →